Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Bloc nerveux du plexus brachial par rapport aux soins standard pour la réduction fermée de la fracture du radius distal chez les adultes - l'essai BLOCK. un essai contrôlé randomisé multicentrique national

16 septembre 2026 mis à jour par: Nordsjaellands Hospital

The aim of the project is to evaluate the beneficial and harmful effects of an ultrasound-guided brachial plexus nerve block for patients with a distal radius (wrist) fracture in the need of realignment of fractured bone endings without cutting the skin (closed reduction), in comparison to a haematoma block, which is standard care in Denmark.

Every participant will receive one of the following types of anaesthesia for the realignment of the wrist fracture:

  1. A nerve block of the arm (plexus brachialis block)
  2. A haematoma block, which is the current standard anaesthesia in the emergency departments.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

1716

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Capital Region
      • Hillerød, Capital Region, Danemark, 3400
        • Copenhagen University Hospital - North Zealand Hillerød

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults (age ≥ 18 years) with a distal radius fracture in need of closed reduction

Exclusion Criteria:

  • Patients who would never qualify for surgery according to local guidelines
  • Lack of informed consent
  • No Danish Central Person Register (CPR) number
  • Allergies to the trial medication
  • Distal radius fracture initially deemed to require surgery regardless of the outcome of the closed reduction
  • Open fractures (fracture-related wound requiring sutures)
  • Other fractures on the same extremity ((NOT including distal ulna fracture(s))
  • Bilateral distal radius fractures both requiring closed reduction
  • Concomitant medical or surgical condition taking priority over the closed reduction of the distal radius fracture.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Intervention group

Ultrasound-guided brachial plexus nerve block. A total of 30 ml of lidocaine (10 mg/ml) with adrenaline (5 ug/ml) will be administered in multiple injections.

The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block

Comparateur actif: Control group

Haematoma block with local anaesthetics i.e. lidocaine with adrenaline

Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Proportion cumulée de patients ayant subi une chirurgie pour fracture du radius distal
Délai: 90 jours après la réduction fermée
90 jours après la réduction fermée

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Composite outcome of treatment related complications
Délai: 90 days after closed reduction

loco-regional neurological complications from affected arm, local anaesthetic systemic toxicity, soft tissue injuries (including skin injuries) related to the closed reduction procedure, infection at the site of needle puncture, vessel puncture requiring subsequent treatment (including compression), pneumothorax, allergic reaction, new bone or joint injury (e.g. dislocation or fracture) after the closed reduction and/or pulmonary embolism

90 days after closed reduction
Patient Rated Wrist Evaluation (PRWE)
Délai: 90 days after closed reduction

The PRWE is a patient-reported outcome and the PRWE-score is calculated from the Danish-validated translation of the PRWE questionnaire

90 days after closed reduction
Maximum pain score in the affected wrist during closed reduction(s)
Délai: 0-12 hours after the closed reduction

The pain outcomes are patient-reported as a Numerical Rating Scale (NRS) score on a scale from 0=no pain to 10=worst pain imaginable. If the patient has the closed reduction performed more than one time, the patient will be asked to report the worst pain experienced during all the attempts of a closed reduction.

0-12 hours after the closed reduction
Proportion of patients with unacceptable radiographic fracture position immediately after closed reduction
Délai: 0 -24 hours after closed reduction

The radiographic fracture position is evaluated according to the American Academy of Orthopaedic Surgerons (AAOS) guidelines. The fracture position is unacceptable if the fracture has a radial shortening > 3 mm, > 10 degrees dorsal tilt of the articular surface of radius from a perpendicular line on the longitudianal axis of radius or intra-articular displacement or step-off > 2 mm.

0 -24 hours after closed reduction

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Nombre de tentatives utilisées pour la réduction fermée
Délai: Immédiatement après la réduction fermée
Immédiatement après la réduction fermée
Proportion de complications individuelles dans le résultat secondaire composite
Délai: 90 jours après la réduction fermée
90 jours après la réduction fermée
Pain at rest in the affected wrist immediately, 90 days, and 12 months after closed reduction
Délai: 0-12 hours, 90 days and 12 months after closed reduction

The pain outcomes are patient-reported as a Numerical Rating Scale (NRS) score on a scale from 0=no pain to 10=worst pain imaginable.

0-12 hours, 90 days and 12 months after closed reduction
Maximum pain in the affected wrist within the first 24 hours after closed reduction
Délai: 24-36 hours after the closed reduction.

The pain outcomes are patient-reported as an NRS score on a scale from 0=no pain to 10=worst pain imaginable.

24-36 hours after the closed reduction.
Proportion of patients with complex regional pain syndrome (CRPS)
Délai: 90 days and 12 months after closed reduction

CRPS is defined according to the Budapest Criteria

90 days and 12 months after closed reduction
Disabilities of the Arm, Shoulder, and Hand (DASH) score
Délai: 90 days and 12 months after closed reduction

DASH-score is calculated from the Danish-validated translation of the DASH questionnaire

90 days and 12 months after closed reduction
Patient Rated Wrist Evaluation (PRWE)
Délai: 12 months after closed reduction

PRWE-score is calculated from the Danish-validated translation of the PRWE questionnaire

12 months after closed reduction
Quality of life (EQ-5D-5L) score
Délai: 90 days and 12 months after closed reduction

The Danish translation of the EQ-5D-5L questionnaire is used and the EQ-5D-5L-score is calculated based on the Danish EQ-5D-5L value set

90 days and 12 months after closed reduction
Difficulty of closed reduction of the fracture
Délai: Immediately after closed reduction

The doctor reported ease on a numeric rating scale from 0-10; 0=very easy, 10=very difficult)

Immediately after closed reduction
Discomfort related to the anaesthetic procedure
Délai: 0-12 hours after closed reduction

The discomfort is a patient-reported outcome on a numeric rating scale from 0-10; 0=no discomfort, 10=very uncomfortable

0-12 hours after closed reduction
Overall satisfaction with the treatment 0 to 24 hours after initiation of the anaesthesia
Délai: 24 hours after closed reduction

The overall satisfaction is a patient-reported outcome on a numeric rating scale from 0-10; 0=very unsatisfied, 10=very satisfied. When evaluating the treatment, the patient is specifically asked to include all elements of the treatment including: the anaesthetic (procedure and following effects), the experience during the closed reduction and the pain and general sensation in the arm/wrist in the first 24 hours after the treatment commencement.

24 hours after closed reduction
Proportion of patients with unacceptable radiographic position at first follow-up in the orthopaedic out-patient clinic (typically 10-14 days post-reduction)
Délai: 10-14 days after closed reduction

The radiographic fracture position is evaluated according to the American Academy of Orthopaedic Surgerons (AAOS) guidelines. The fracture position is unacceptable if the fracture has a radial shortening > 3 mm, > 10 degrees dorsal tilt of the articular surface of radius from a perpendicular line on the longitudianal axis of radius or intra-articular displacement or step-off > 2 mm.

10-14 days after closed reduction
Proportion of patients having one or more serious adverse events (SAEs), including events related to loss of hand function
Délai: Within 90 days after closed reduction

A SAE is defined as an adverse event that leads to the following incidents:

  • Death
  • Life threatening injury or disease
  • Severe or permanent disability
  • Admission to the hospital or prolongation of hospitalisation

Surgical reduction of the distal radius fracture, including relevant admission to hospital, will not be catagorised as a SAE.

Within 90 days after closed reduction
Proportion of patients having one or more adverse events (AEs)
Délai: Within 24 hours after closed reduction

An AE is defined as any harmful and unintended event, sign, or symptom, that appear during the trial period, regardless of whether this AE is considered related to the treatment or not.

Within 24 hours after closed reduction

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Cecilie D Harwood, MD, PhD-fellow, Copenhagen University Hospital - North Zealand
  • Chercheur principal: Anne-Sofie Jellestad, MD, PhD-fellow, Copenhagen University Hospital - North Zealand

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 décembre 2024

Achèvement primaire (Estimé)

24 novembre 2026

Achèvement de l'étude (Estimé)

24 août 2027

Dates d'inscription aux études

Première soumission

6 novembre 2024

Première soumission répondant aux critères de contrôle qualité

6 novembre 2024

Première publication (Réel)

7 novembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner